Abcuro Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
2ndary - Private
- Investors
-
17
Abcuro General Information
Description
Developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer. The company uses proprietary analysis of transcription data from human disease to identify new approaches to target key compartments of the immune system, enabling healthcare professionals to plan appropriate procedures for efficient treatments.
Contact Information
Website
www.abcuro.comCorporate Office
- 55 Chapel Street
- Suite 200
- Newton, MA 02458
- United States
Corporate Office
- 55 Chapel Street
- Suite 200
- Newton, MA 02458
- United States
Abcuro Timeline
Abcuro Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 5. Later Stage VC (Series B) | 11-Aug-2023 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series A1) | 07-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 01-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 09-Nov-2018 | $8M | $10.2M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 13-Dec-2016 | $2.25M | $2.25M | Completed | Clinical Trials - Phase 1 |
Abcuro Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | 1,619,201 | $0.001000 | $0.3 | $4.94 | $4.94 | 1x | $4.94 | 3.29% |
| Seed | 671,141 | $0.001000 | $3.35 | $3.35 | 1x | $3.35 | 1.36% |
Abcuro Comparisons
Industry
Financing
Details
Abcuro Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Atara Biotherapeutics | Formerly VC-backed | Thousand Oaks, CA |
Abcuro Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Abcuro Patents
Abcuro Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3227742-A1 | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies | Pending | 26-Jul-2021 | ||
| EP-4377346-A1 | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies | Pending | 26-Jul-2021 | ||
| AU-2022320627-A1 | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies | Pending | 26-Jul-2021 | ||
| JP-2024528877-A | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibody | Pending | 26-Jul-2021 | ||
| EP-4314066-A1 | Anti-klrg1 antibodies | Pending | 26-Mar-2021 | C07K16/2851 |
Abcuro Executive Team (14)
| Name | Title | Board Seat |
|---|---|---|
| Steven Greenberg MD | Co-Founder & Chief Scientific Officer | |
| Richard Motschwiller | Vice President of Finance and Planning | |
| Alex Martin | Chief Executive Officer & Board Member | |
| Karen Tubridy | Chief Operating Officer | |
| H. Wilkins MD | Chief Medical Officer |
Abcuro Board Members (20)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alex Martin | Self | Chief Executive Officer & Board Member | |
| Darlene Hicks | Self | Board Member & Audit Committee Chairman | |
| Iyona Rajkomar | Pontifax Venture Capital | Board Member | |
| Jason Hafler Ph.D | Sanofi Ventures | Board Member | |
| Julius Knowles Ph.D | Mass General Brigham Ventures | Board Member |
Abcuro Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Abcuro Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
| BlackRock | Asset Manager | Minority | ||
| Eurofarma Ventures | Corporate Venture Capital | Minority | ||
| New Leaf Venture | Venture Capital | Minority | ||
| Redmile Group | Hedge Fund | Minority |
Abcuro FAQs
-
When was Abcuro founded?
Abcuro was founded in 2015.
-
Who is the founder of Abcuro?
Steven Greenberg MD, Stefano Gulla Ph.D, and Kenneth Thompson Ph.D are the founders of Abcuro.
-
Who is the CEO of Abcuro?
Alex Martin is the CEO of Abcuro.
-
Where is Abcuro headquartered?
Abcuro is headquartered in Newton, MA.
-
What is the size of Abcuro?
Abcuro has 21 total employees.
-
What industry is Abcuro in?
Abcuro’s primary industry is Drug Discovery.
-
Is Abcuro a private or public company?
Abcuro is a Private company.
-
What is Abcuro’s current revenue?
The current revenue for Abcuro is .
-
How much funding has Abcuro raised over time?
Abcuro has raised $207M.
-
Who are Abcuro’s investors?
Bain Capital Life Sciences, BlackRock, Eurofarma Ventures, New Leaf Venture, and Redmile Group are 5 of 17 investors who have invested in Abcuro.
-
Who are Abcuro’s competitors?
Kite Pharma, Alector, Agenus, Incyte, and Atara Biotherapeutics are some of the 6 competitors of Abcuro.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
